TIDMCOG
Cambridge Cognition Holdings PLC
19 March 2020
19 March 2020
Cambridge Cognition Holdings Plc
(" Cambridge Cognition" or the "Company")
Cambridge Cognition awarded Innovative Medicines Initiative
grant
with partners from industry and academia
Cambridge Cognition Holdings plc (AIM: COG), which develops and
markets digital solutions to assess all aspects of cognition, is
pleased to announce it is part of a successful consortium of 46
industry and academic partners who have collectively been awarded a
prestigious Innovative Medicines Initiative ("IMI") grant. Led by
the University of Newcastle, the consortium will work to identify
digital endpoints for fatigue, sleep and activities of daily living
in neurodegenerative disorders and immune-mediated inflammatory
diseases. Cambridge Cognition will be the computerised cognitive
assessment partner in the consortium and the proportion of the
grant received by the Company is anticipated to be EUR150,000.
The IMI grant will fund a new European research project to
Identify Digital Endpoints to Assess FAtigue, Sleep and acTivities
of daily living (acronym: "IDEA-FAST") in the following
neurodegenerative disorders: Parkinson's disease and Huntington's
disease, and in the following immune-mediated inflammatory
diseases: rheumatoid arthritis, systemic lupus erythematosus,
primary Sjögren's syndrome, and inflammatory bowel disease; has
been launched.
IDEA-FAST is a ground-breaking, EUR42 million digital health
project co-funded by the European Union (represented by the
European Commission) and the European pharmaceutical industry
(represented by EFPIA, the European Federation of Pharmaceutical
Industries and Associations) under the Innovative Medicines
Initiative Joint Undertaking programme. It consists of 46 members
from 14 different European countries, including Cambridge
Cognition, pharmaceutical companies, academic and not-for-profit
institutions, small- and medium-sized enterprises and patient
organisations aiming to play complementary roles in achieving the
agreed goals.
Fatigue and sleep disturbances are common and disabling symptoms
that affect patients with neurodegenerative disorders and
immune-mediated inflammatory diseases impacting on daily
activities; they are the major causes of poor quality of life and
increased healthcare cost. Current questionnaire-based approaches
to measure these symptoms have key limitations preventing them from
being used as reliable endpoints in clinical trials to evaluate the
effect of therapies.
Based on the advancement of wearable and portable digital
technology, IDEA-FAST aims to address these issues by identifying
novel digital endpoints for fatigue, sleep disturbances and
disabilities in daily activities. The final goal is to provide more
objective, sensitive, reliable and ecological measures of the
severity and impact of these symptoms in real-world settings. Such
digital endpoints will eventually improve the efficiency of
clinical trials, ultimately reducing the time and cost to bringing
new therapies to patients.
The project, over its planned 66 month duration, will consist of
two phases: an initial pilot study for testing and prioritising
several digital devices and to identify candidate digital
endpoints, followed by a large longitudinal study to validate
findings for the most promising digital endpoints. The project will
seek advice from regulatory agencies, including the European
Medicines Agency, for the initial qualification of these digital
endpoints. Patient users' perspective, data privacy, ethical, legal
and other regulatory issues will be taken into consideration at all
stages of the project.
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:
"With advances in digital technology, and the widespread
adoption of devices, data on patients' functional outcomes can now
be gathered at high-frequency in an objective and quantifiable
manner. This offers huge potential for identifying and validating
digital endpoints in clinical trials, and we are pleased to be the
computerised cognitive assessment partner for this important
collaborative initiative."
For further information, contact:
Cambridge Cognition Holdings PLC Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Nick Walters, Chief Financial Officer
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Manasa Patil (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Originally developed at Cambridge University, CANTAB(TM)
technology has been continually enhanced by Cambridge Cognition for
over a decade. CANTAB(TM) technology has been extensively used in
research, resulting in over 2,300 peer-reviewed research papers,
more than any other computerized cognitive test. These include
nearly three hundred publications in neurodegenerative inflammatory
disorders. The technology includes secure, cloud-based servers for
data storage and study management. The company has an excellent
track record of translating neuroscience research into successful
products for healthcare and clinical research. Cambridge Cognition
have extensive experience in developing scientifically robust and
engaging cognitive assessments on new technology platforms,
including wearable devices, mobile phones and using automated
speech recognition.
For the IDEA-FAST project, Cambridge Cognition will contribute
digital tools for the assessment of the cognitive components of
fatigue using both the CANTAB(TM) battery and high-frequency brief
assessments. They will also bring their expertise of cognitive
assessments to bear on the data analysis effort.
https://www.cambridgecognition.com/
About IDEA-FAST
IDEA-FAST is led by Newcastle University, Great Britain, and
University Hospital Schleswig-Holstein, Kiel, Germany as academic
co-leaders, and by Janssen Pharmaceutica NV and Takeda
Pharmaceuticals International as industry co-leaders.
See https://www.idea-fast.eu/ for more details.
About the Innovative Medicines Initiative and the European
Federation of Pharmaceutical Industries and Associations
IMI is Europe's largest public-private initiative aiming to
speed up the development of better and safer medicines for
patients. IMI supports collaborative research projects and builds
networks of industrial and academic experts in order to boost
pharmaceutical innovation in Europe. IMI is a joint undertaking
between the European Commission and EFPIA.
See https://www.imi.europa.eu/ and https://www.efpia.eu/ for
more details.
Acknowledgement
This project has received funding from the Innovative Medicines
Initiative 2 Joint Undertaking (JU) under grant agreement No
853981. The JU receives support from the European Union's Horizon
2020 Research and Innovation Programme and EFPIA and Parkinson's
Disease Society of the United Kingdom LBG.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABRGDXUUBDGGI
(END) Dow Jones Newswires
March 19, 2020 03:00 ET (07:00 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024